Table 2.
Patient, tumor and treatment characteristics for mastectomy patients with and without radiotherapy
| Characteristic | (+) Radiotherapy | (−) Radiotherapy |
|---|---|---|
| Frequency, n | 103 | 250 |
| BRCA gene mutation (P = 0.025) | ||
| 1 | 48 (46.6) | 149 (59.6) |
| 2 | 66 (53.4) | 101 (40.4) |
| Clinical stage (P < 0.0001)a | ||
| 1 | 16 (15.5) | 129 (51.6) |
| 2 | 55 (53.4) | 115 (46.0) |
| 3 | 31 (30.1) | 6 (2.4) |
| Unknown | 1 (1.0) | 0 |
| T-stage (P = 0.0001) | ||
| T0/T1 | 43 (41.8) | 160 (64.0) |
| T2 | 42 (40.8) | 83 (33.2) |
| T3 | 15 (14.6) | 1 (0.4) |
| T unknown | 3 (2.9) | 6 (2.4) |
| Nodal surgery | ||
| Total lymph nodes removed (P = 0.004) | ||
| Mean (Std. Dev.) | 16.9 (8.9) | 13.8 (8.1) |
| Median | 15 | 14 |
| Minimum-Maximum | 5–51 | 1–40 |
| Positive lymph nodes removed (P < 0.0001) | ||
| 0 | 33 (32.0) | 190 (76.3) |
| 1–3 | 30 (29.1) | 46 (18.5) |
| 4+ | 40 (38.8) | 13 (5.2) |
| Chemotherapy (P = 0.02)a | ||
| No | 23 (22.3) | 85 (34.0) |
| Yes | 79 (76.7) | 152 (60.8) |
| Unknown | 1 (1.0) | 13 (5.2) |
| Prophylactic contralateral mastectomy (P = 0.01)a | ||
| No | 71 (68.9) | 143 (57.2) |
| Yes | 28 (27.2) | 106 (42.4) |
| Unknown | 4 (3.9) | 1 (0.4) |
a
Comparison between surgical groups made omitting the unknown/missing category